Evidence map›Paper›PMID 36046144›Full record

ReviewExploration of targeted anti-tumor therapy2021

Potential benefit of β-glucans as adjuvant therapy in immuno-oncology: a review.

Valeria Cognigni, Nicoletta Ranallo, Francesca Tronconi, Francesca Morgese, Rossana Berardi

Open access · diamondAbstract readReview
In one paragraph

Review in Exploration of targeted anti-tumor therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 25 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 2 countries.

Valeria CognigniClinical Oncology, Università Politecnica delle Marche, AOU Ospedali Riuniti, 60126 Ancona, Italy.
Nicoletta RanalloClinical Oncology, Università Politecnica delle Marche, AOU Ospedali Riuniti, 60126 Ancona, Italy.
Francesca TronconiClinical Oncology, Università Politecnica delle Marche, AOU Ospedali Riuniti, 60126 Ancona, Italy.
Francesca MorgeseClinical Oncology, Università Politecnica delle Marche, AOU Ospedali Riuniti, 60126 Ancona, Italy.
Rossana BerardiClinical Oncology, Università Politecnica delle Marche, AOU Ospedali Riuniti, 60126 Ancona, Italy.ORCID https://orcid.org/0000-0002-9529-2960
Marche Polytechnic University · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fungal compounds have long been used for centuries as food supplements. β-glucans have been identified as the most interesting molecules with beneficial effects in several chronic diseases.

Indexed as

immune checkpoint inhibitorsimmune-modulatingimmuno-oncologymushroomsβ-glucans

Identifiers

PMID36046144
PMCPMC9400766
OpenAlexW3133606251

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.